New RestoraFIBRE® Daily Gummies offers convenient source of fibre
07 Apr 2021
RestoraFIBRE Daily Gummies contains inulin, a prebiotic fibre which helps support a healthy digestive system and promote regularity
TORONTO, April 7, 2021 /CNW/ - Bayer Inc. is excited to announce that Canadians now have a convenient new everyday source of fibre to help support and maintain a healthy digestive system. RestoraFIBRE Daily Gummies helps provide Canadians with the supplemental fibre they may need — in a great-tasting, chewable gummy form.
RestoraFIBRE Daily Gummies contain inulin, which is both a soluble fibre and a prebiotic that helps encourage growth of healthy bacteria in the gut. When fed well, these bacteria (such as bifidobacteria) help to maintain a healthy gut and support a healthy digestive system. The importance of prebiotics and fibre in the diet has been noted and most Canadians are only getting about half of their required fibre intake.1
"RestoraFIBRE Daily Gummies grows our family of RestoraLAX constipation products," says Gerry Cruz, Brand Manager Digestive Health, Bayer.
Two RestoraFIBRE Daily Gummies taken twice a day provides 8 grams of soluble, naturally sourced fibre to help support regularity and can help adults meet their daily fibre requirements. The gummies also help provide gentle relief of constipation and irregularity.
RestoraFIBRE Gummies offer six great-tasting fruit flavours per bottle in either 30-count or 90-count bottles. Learn more at
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to .
SOURCE Bayer Inc.
Organizations
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.